Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

Groundbreaking longevity research initiative brings together leading scientists and institutions to decode the genetic basis ...

In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...

We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to ...

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock ...

We recently compiled a list of Billionaire Prem Watsa’s 10 Stock Picks With Highest Potential. In this article, we are going ...

Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 ...

Health-care companies ticked up as traders awaited earnings. Shares of Big Pharma company Merck ticked down ahead of its earnings. Summit Therapeutics shares rallied after its lung cancer drug ...

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Q1 2025 Results Conference Call April 23, 2025 6:30 AM ETCompany ParticipantsTuukka Hirvonen - Head of IRLiisa Hurme ...

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it seems a key part of that effort will come ...